Orgenesis Inc.

ORGS Healthcare Biotechnology

Orgenesis Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.0 million, up 95.3% from fiscal 2023. In the quarter to December 2024, revenue grew 82.4%, EPS fell 211.9% and free cash flow fell 317.9%, each against the same quarter a year earlier.

0.06 0.06 Infinity
Market cap
$5.7M
P/E
0.0×
Fwd P/E
1.0×
Dividend yield
—
F-score
3/9
Altman Z
−352.42
Beneish M
n/a
Dividend safety
n/a
Older periods Mar '24 Jun '24 Sep '24 Dec '24
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
36.44 38.10 23.39 7.69
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(4.34) (4.27) (4.54) (3.79)
P/B ratio
0.00 0.00 0.00 0.00
Price to Tangible BV
0.00 0.00 0.00 0.00
EV/Sales
84.55 53.23 38.98 23.15
EV/EBITDA
0.00 0.00 0.00 0.00
EV/Operating CF
(3.72) (2.93) (2.26) (1.40)
EV/FCF
(3.43) (2.81) (2.23) (1.38)
Quick Ratio
0.03 0.04 0.04 0.03
Current Ratio
0.07 0.07 0.07 0.03
Net Debt/EBITDA
(2.98) (2.83) (1.78) (0.90)
Debt/Assets
84.14% 36.55% 50.98% 1,235.53%
Debt/Equity
(0.94) (0.71) (0.63) (0.44)
Asset Turnover
0.01 0.03 0.04 0.13
Operating CF/Net income
0.45 0.66 0.51 0.10
Capex/Depreciation
(0.54) 0.00 (0.11) 0.00
Interest Coverage
(10.48) (5.21) (11.69) (8.57)
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
4,295.04% 837.80% 767.72% 1,342.52%
Intangible Assets out of Total Assets
0.33 0.32 0.33 0.00
Share Based Compensation of Revenue
221.28% 253.66% 466.57% 212.29%
Graham Net Nets
(2.93) (1.75) (2.43) (4.79)
Graham Number
36.28 26.78 31.22 48.05
Earnings Yield
(121.26%) (120.88%) (191.35%) (608.99%)
Free Cash Flow Yield
(67.72%) (49.71%) (74.86%) (217.87%)
Revenue per Share
0.04 0.06 0.07 0.07
Operating CF per Share
(1.34) (1.52) (0.98) (0.50)
Capex per Share
(0.06) 0.00 (0.01) 0.00
Free Cash Flow per Share
(1.40) (1.52) (0.99) (0.50)
Cash per Share
0.17 0.30 0.24 0.16
Shareholders Equity per Share
(8.30) (4.06) (5.07) (8.91)
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
(8.30) (4.06) (5.07) (8.91)
Free Cash Flow
(4.64) (5.91) (4.69) (2.10)
Working Capital
(27.07) (29.35) (33.53) (26.16)
Capital Expenditures
(0.20) 0.00 (0.06) 0.00
Net Current Asset Value
(56.51) (44.02) (51.10) (38.12)
EV/EBIT
0.00 0.00 0.00 0.00
Capex to Sales
1.45 0.00 0.17 0.00
Price to Operating Income
0.00 0.00 0.00 0.00
Other line items
Average Receivables
10.80 0.61 0.64 0.29
Average Payables
10.40 8.69 9.51 9.85
Average Inventory
0.08 — — —
Average Assets
52.54 24.32 23.61 7.95
Average Common Equity
(8.78) (14.26) (19.65) (29.26)

Fold the line items

Columns are period end dates